Study on Inhibitory Effects in vivo and in vitro of Gemcitabine on Liver Cancer
10.6039/j.issn.1001-0408.2015.28.18
- VernacularTitle:吉西他滨的体内外抗肝癌作用研究
- Author:
Jiayue SUN
;
Jing ZUO
;
Yiguang JIN
- Publication Type:Journal Article
- Keywords:
Gemcitabine;
Liver cancer;
Cell;
Solid tumor;
in vivo;
in vitro
- From:
China Pharmacy
2015;(28):3941-3943
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To study inhibitory effects in vivo and in vitro of gemcitabine on liver cancer. METHODS:MCF-7 cells and HepG2 cells were treated with different concentrations of gemcitabine solutions(5,10,20,30,50,70 and 90 μmol/L). The absorbance of cells was determined by MTT assay after treated for 24,48 and 72 h. The inhibition ratio and 50% inhibiting concentration(IC50) of cells were calculated. Tumor-bearing mice were established by inoculating 0.2 ml liver cancer H22 cell line via right anterior axillary,and then randomly divided into control group(normal saline)and gemcitabine group(40 mg/kg)with 5 mice in each group. They were given relevant medicine intravenously every 2 days,for 3 times. The changes of body weight and in-hibition ratios were recorded. RESULTS:Gemcitabine can inhibit MCF-7 cells and HepG2 cells,and IC50 of gemcitabine to them were 30 and >90 μmol/L within 24 h respectively,and those of gemcitabine to them were all lower than 5 μmol/L after 48 h and 72 h. There was no statistical significance in body weight of tumor-bearing mice between 2 groups,and inhibitory rate of gemcitabi-ne to H22 cell line was 75.76%. CONCLUSIONS:Gemcitabine can inhibit liver cancer in vivo and in vitro.
